Home > Healthcare > Molecular Quality Controls Market
Molecular Quality Controls Market Size
Molecular Quality Controls Market size will gain noticeable traction between 2024 and 2032, driven by the increase in cases of genetic disorders, HIV, cancers, and other diseases. Of late, there has been an influx of stringent regulatory requirements for mandating the use of quality control measures. Regulatory bodies, such as the FDA and EMA require laboratories to implement quality control procedures to maintain the accuracy and reliability of diagnostic tests, further driving the adoption of molecular quality controls.
As the complexity of molecular tests increases, the need for high-quality control materials that accurately mimic patient samples becomes more critical. Manufacturers are innovating to develop molecular quality controls that closely resemble clinical specimens, enabling laboratories to validate and monitor the performance of their molecular assays effectively. Furthermore, the increasing prevalence of chronic diseases and infectious outbreaks worldwide will fuel the demand for molecular testing.
Molecular Quality Controls Market Trends
Another significant factor driving the industry expansion is the increasing demand for customizable quality control materials tailored to specific molecular diagnostic assays and laboratory requirements. This customization enables laboratories to optimize their processes and ensure the accuracy and reliability of test results. Moreover, the integration of digital technologies, such as cloud-based platforms and data analytics is enhancing the management and analysis of quality control data, providing labs with valuable insights to improve testing efficiency and compliance.
The ongoing conflict between Russia and Ukraine can also have several implications for various industries, including the molecular quality control market. The sanctions imposed by the international community on Russia due to its actions in Ukraine can lead to a decrease in the import and export of goods and services, further causing disruptions in the supply chain of molecular quality controls. The instability in the region can also affect investment and business confidence, which can impact the industry gains to some extent.
Molecular Quality Controls Market Analysis
Based on application, the oncology segment is expected to record extensive gains by 2032, driven by the rising research activities on cancer and associated biomarkers. According to the European Society of Medical Oncology, the incidence of cancer will increase by almost 21% by 2040. New efforts related to biomarker discovery will also supplement the expansion of molecular quality controls in oncology.
Geographically, the Asia Pacific molecular quality controls market size is poised to expand by 2032, due to the increased demand for accurate and high-quality diagnostic tests. With cancer becoming a key health concern, the requirement for precision oncology has been a major area of focus for various authorities in the region. The presence of an aging population and changing lifestyles have led to the establishment of various initiatives. Some of them include the introduction of platforms such as Japan’s LC-SCRUM lung cancer genomic screening project and the Korean Cancer Precision Medicine Diagnosis & Treatment Enterprise (K-MASTER) in South Korea.
Molecular Quality Controls Market Share
Some of the major players in the industry include:
- Abbott Laboratories
- Bio-Rad Laboratories Inc
- Quidel Corporation
- Microbiologics Inc
- Molecular Quality Controls Inc.
- Thermo Fisher Scientific
- SeraCare Life Sciences Inc
- Roche Diagnostics
- ZeptoMetrix Corporation (Antylia Scientific).
These firms are actively pursuing growth-driven initiatives, such as partnerships, acquisitions, mergers and technology advancements to bolster their global presence.
Molecular Quality Controls Industry News
- In February 2023, Element Biosciences, Inc., and Bio-Rad Laboratories, collaborated to exhibit the capabilities of the latter’s SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.